Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy

Overview of attention for article published in JNCI: Journal of the National Cancer Institute, August 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

So far, Altmetric has seen 37 X posts from 23 X users, with an upper bound of 121,855 followers.

RT @JNCI_Now: Clinical implications of BMI in patients with metastatic breast cancer treated with abemaciclib and endocrine therapy #bcsm @…

RT @JNCI_Now: Clinical implications of BMI in patients with metastatic breast cancer treated with abemaciclib and endocrine therapy #bcsm @…

RT @JNCI_Now: Clinical implications of BMI in patients with metastatic breast cancer treated with abemaciclib and endocrine therapy #bcsm @…

RT @JNCI_Now: Clinical implications of BMI in patients with metastatic breast cancer treated with abemaciclib and endocrine therapy #bcsm @…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 33 additional X posts.